The Charlson Comorbidity Index Predicts Poor Prognosis in Elderly AML Patients

Basit Öğe Kaydı
dc.contributor.authorTığlıoğlu, Mesut
dc.contributor.authorAlbayrak, Murat
dc.contributor.authorTığlıoğlu, Pınar
dc.contributor.authorYıldız, Abdulkerim
dc.contributor.authorDoğan, Servihan
dc.contributor.authorAfacan Öztürk, Hacer Berna
dc.contributor.authorMaral, Senem
dc.contributor.authorSağlam, Buğra
dc.contributor.authorAras, Merih Reis
dc.contributor.authorDilek, İmdat
dc.date.accessioned2024-02-01T12:09:15Z
dc.date.available2024-02-01T12:09:15Z
dc.date.issued2023en_US
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractAcute myeloid leukemia (AML) is the most common type of acute leukemia in adults and patients older than 65 years have a poor prognosis. Patient-related factors, such as comorbid conditions that affect performance status, and insufficient organ functions, explain why elderly patients have a worse prognosis. The Charlson Comorbidity Index (CCI), is used to predict prognosis according to comorbidities. This retrospective study was conducted on patients diagnosed with AML between 2010 and 2019. Patients >60 years were included. Demographic information, comorbidities, CCI, ECOG ( Eastern Cooperative Oncology Group) score, cytogenetic characteristics, treatment regimens, treatment response, follow-up periods were recorded for all patients. Evaluation was made of a total of 82 patients with a mean age of 71.18 ± 7.67. The median follow-up was 6.7 months. The median number of comorbidities was 1 [0.0-4.0] with the median CCI score of 3 [2.0-6.0]. Median overall survival (OS) was 7.0 months [3.1-10.8] and PFS was 6.8 months [3.6-10.0]. As the median CCI score was 3, patients were divided into two groups as CCI > 3 and CCI ? 3. Age, gender, ECOG, cytogenetic risk profile, first-line treatment and CR1 achievement status were all similar in both groups (p > 0.05). Patients with CCI > 3 had significantly shorter OS than patients with CCI ? 3 (3.6 months [0.3-29.3] vs 8.6 months [0.2-60.2], p= 0.049). The results of the current study demonstrated that CCI, can be used as a prognostic index in elderly patients with AML independently of other patient and disease-related characteristics.
dc.description.provenanceSubmitted by Zeynep Umut NARİN (umutarslan@hitit.edu.tr) on 2024-02-01T12:09:04Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Zeynep Umut NARİN (umutarslan@hitit.edu.tr) on 2024-02-01T12:09:15Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2024-02-01T12:09:15Z (GMT). No. of bitstreams: 0 Previous issue date: 2023en
dc.identifier.citationTiglioglu, M., Albayrak, M., Tiglioglu, P., Yildiz, A., Dogan, S., OZTURK, H. B. A., ... & Dilek, I. (2020). The Charlson Comorbidity Index Predicts Poor Prognosis in Elderly AML Patients. International Journal of Hematology and Oncology, 33(1), 001-007.
dc.identifier.doi10.4999/uhod.236829
dc.identifier.issn1306-133X
dc.identifier.scopusqualityQ4
dc.identifier.urihttps://hdl.handle.net/11491/8783
dc.identifier.wosWOS:000961062400001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorYıldız, Abdulkerim
dc.language.isoen
dc.publisherAKAD DOKTORLAR YAYINEVI
dc.relation.ispartofUHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAMLen_US
dc.subjectElderlyen_US
dc.subjectComorbidityen_US
dc.subjectCharlsonen_US
dc.subjectPrognosisen_US
dc.titleThe Charlson Comorbidity Index Predicts Poor Prognosis in Elderly AML Patients
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu